

**Mercy Oyugi, Sarah Rogstad**

**Center for Drug Evaluation and Research (CDER), U.S. Food and Drug Administration (Silver Spring, MD)**

**INTRODUCTION**

Multi-attribute method (MAM) is a liquid chromatography-high resolution mass spectrometry (LC-HRMS) technique for monitoring product quality attributes (PQAs) in therapeutic proteins. MAM also has a new peak detection (NPD) feature for monitoring non-targeted peaks. MAM has been proposed as a replacement for conventional quality control (QC) tests for therapeutic proteins. The Office of Testing and Research (OTR) has developed an in-house MAM approach using rituximab as the model protein. Here, the in-house MAM approach was used to analyze stressed rituximab samples with the aim of assessing MAM's capability to monitor stress-induced changes in rituximab PQA levels and new peaks.

**METHODS**

**Stress Conditions and LC-MS Experiments**

- The stress conditions were: hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>) (0.05% and 0.1%, 5 hours at 4 °C); pH 3.4 and pH 10.0 (room temperature for 24 and 72 hours); 50 °C (24 and 72 hours); and UV (480 and 1440 Whr/m<sup>2</sup>) plus Vis light (1200 kluxhr)
- Tryptic rituximab digests were separated on an Agilent Zorbax C18 300-SB column using a Thermo Accela LC system coupled with a Thermo QE hybrid quadrupole-orbitrap mass spectrometer.
- Spectra were acquired in positive ion mode (300-1800 m/z), with a resolution of 140,000, AGC target of 3e6 and max IT of 200 ms.

**Targeted PQA processing**


- Raw LC-MS files were imported into Chromeleon for PQA identification and quantification.
- Genesis algorithm was used for AUC integration, and the sum of all observable m/z for the top four isotopes at each charge state were used to calculate areas.
- The 21 rituximab PQAs monitored include methionine oxidation, lysine clipping, deamidation, pyroglutamination, and N-glycosylation.

**New Peak Detection (NPD)**


- NPD was performed using non-stressed controls as reference.
- NPD parameters were: 300-1800 m/z range; 10 ppm m/z width; 0-70 min retention time; 1 min frame time width; 16,000 maximum frames; and 0.5% peak intensity threshold.
- NPD filter rules were: PR element = 0; PR size > 1; charge between +2 and +5; ratio > 10.0.
- Rituximab peptide mapping results from a previous Proteome Discoverer search were used to identify the new peaks.

**RESULTS**

The plots below represent select trends observed for the various stress conditions. In each plot, error bars represent standard deviation of triplicate measurements, while asterisks (\*) denote significant variations based on > 20.0% deviation from the control, and ANOVA tests (p ≤ 0.05).




**FIGURE 1:** Effect of H<sub>2</sub>O<sub>2</sub> treatment on oxidation levels. Heavy chain (HC) Met256 and Met432 increased by up to 60 % compared to control. Smaller increases of 0.5-2.0% in oxidation levels were observed for HC Met20, Met34, Met81, and light chain (LC) Met21 oxidation (data not shown).



**FIGURE 2:** Effect of pH on deamidation. Increased Met256 and Met432 oxidation was also observed for both pH 3.4 and pH 10.0 at the 72 hour incubation period (data not shown).

**FIGURE 3:** Effect of 50 ° C temperature on light chain pyroglutamination. Similar trends were observed for HC pyroglutamination and all six methionine oxidation sites (data not shown).




**FIGURE 4:** Effect of UV and Vis light exposure on oxidation. Similar trends were observed for HC Met20, Met34, and Met81 oxidation, as well as for LC Met21 oxidation (data not shown).

**RESULTS (CONT'D)**

Peptide sequence	Chain	Missed cleavages	m/z	Charge	Observed monoisotopic mass (Da)	Retention time (min)	Modification	Possible source of new peak
VVSVLTVLHQD WLNK	Heavy	0	603.3384	3	1806.9933	52.58	N319 deamidation	Alkaline pH of the trypsin digestion buffer
VSNKALPAPIEK	Heavy	1	423.2583	3	1266.7532	21.77	N329 deamidation	
VEAEDAATYYC QQWTSNPPTFG GGTKLEIK	Light	1	1121.8483	3	3362.5230	43.5	C87 carboxymethyl	Reduction and alkylation during sample preparation
SSSTAYMQLSSL TSEDSAVYYCAR	Heavy	0	1339.5750	2	2678.1336	41.17	C96 carboxymethyl	
ADYEKHKVYAC EVTHQGLSSPV K	Light	2	550.4710	5	2748.3206	18.17	C194 carboxymethyl	
VVSVLTVLHQD WLNKKEYCK	Heavy	2	630.0823	4	2517.3046	47.38	C325 carboxymethyl	Missed cleavage
EPQVYTLPPSRD ELTK	Heavy	1	624.9932	3	1871.95785	24.49	None	
QTPGRGLEWIG AIVPGNGDTSYN QK	Heavy	1	908.1063	3	2722.29745	41.87	None	

**TABLE 1:** New peaks detected by NPD analysis and identified using Proteome Discoverer peptide mapping. Modified amino acid residues are highlighted in red. A total of 34 distinct peaks were detected using NPD analysis. Peaks not shown here could not be identified using Proteome Discover.



**FIGURE 5:** MAM precision for the stress study. The higher CV > 15.0% observed for methionine oxidation can be mitigated by adding 10 – 20 mM methionine to the sample processing buffers.

**CONCLUSIONS**

- The results show that MAM can detect stress-induced changes and variations in PQA levels.
- Additionally, the assessment of the NPD feature has shown that MAM can also reliably track new peaks in stressed samples.
- Overall, these results demonstrate MAM's potential as a quality control method for therapeutic proteins.

**DISCLAIMER**

This poster reflects the views of the author and should not be construed to represent FDA's views or policies.